|
ES2382879T3
(es)
|
2005-09-14 |
2012-06-14 |
Ucb Pharma, S.A. |
Conjugado de anticuerpo - polímero de peine.
|
|
JP5183484B2
(ja)
|
2005-12-09 |
2013-04-17 |
ユセベ ファルマ ソシエテ アノニム |
ヒトil−6に対して特異性を有する抗体分子
|
|
MX2009002855A
(es)
*
|
2006-09-15 |
2009-03-30 |
Enzon Pharmaceuticals Inc |
Profarmacos polimericos dirigidos que contienen enlazadores multifuncionales.
|
|
GB0620729D0
(en)
|
2006-10-18 |
2006-11-29 |
Ucb Sa |
Biological products
|
|
US9319225B2
(en)
|
2007-01-16 |
2016-04-19 |
Microsoft Technology Licensing, Llc |
Remote device waking using a multicast packet
|
|
JP5592792B2
(ja)
|
2007-09-26 |
2014-09-17 |
ユセベ ファルマ ソシエテ アノニム |
二重特異性抗体の融合体
|
|
EP2050764A1
(de)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Neues polyvalentes bispezifisches Antikörperformat und Verwendung
|
|
GB0800277D0
(en)
|
2008-01-08 |
2008-02-13 |
Imagination Tech Ltd |
Video motion compensation
|
|
US8034396B2
(en)
|
2008-04-01 |
2011-10-11 |
Tyco Healthcare Group Lp |
Bioadhesive composition formed using click chemistry
|
|
GB0807413D0
(en)
|
2008-04-23 |
2008-05-28 |
Ucb Pharma Sa |
Biological products
|
|
GB0900425D0
(en)
|
2009-01-12 |
2009-02-11 |
Ucb Pharma Sa |
Biological products
|
|
EP2398498B1
(de)
|
2009-02-17 |
2018-09-05 |
UCB Biopharma SPRL |
Für humanes ox40 spezifische antikörpermoleküle
|
|
US9375699B2
(en)
|
2009-02-21 |
2016-06-28 |
Sofradim Production |
Apparatus and method of reacting polymers by exposure to UV radiation to produce injectable medical devices
|
|
US8968818B2
(en)
|
2009-02-21 |
2015-03-03 |
Covidien Lp |
Medical devices having activated surfaces
|
|
US8663689B2
(en)
|
2009-02-21 |
2014-03-04 |
Sofradim Production |
Functionalized adhesive medical gel
|
|
CA2753171A1
(en)
|
2009-02-21 |
2010-08-26 |
Sofradim Production |
Crosslinked fibers and method of making same using uv radiation
|
|
EP2398583B1
(de)
|
2009-02-21 |
2020-12-23 |
Sofradim Production |
Vorrichtung und verfahren zum reagieren von polymeren, die durch eine metallion matrix laufen, zur herstellung von injizierbaren medizinischen vorrichtungen
|
|
US8535477B2
(en)
*
|
2009-02-21 |
2013-09-17 |
Sofradim Production |
Medical devices incorporating functional adhesives
|
|
US8968733B2
(en)
*
|
2009-02-21 |
2015-03-03 |
Sofradim Production |
Functionalized surgical adhesives
|
|
CA2753162A1
(en)
|
2009-02-21 |
2010-08-26 |
Sofradim Production |
Amphiphilic compounds and self-assembling compositions made therefrom
|
|
US8648144B2
(en)
|
2009-02-21 |
2014-02-11 |
Sofradim Production |
Crosslinked fibers and method of making same by extrusion
|
|
EP2398519A2
(de)
|
2009-02-21 |
2011-12-28 |
Sofradim Production |
Verbindungen und mit solvophoben linkern aktivierte medizinische vorrichtungen
|
|
CA2753173C
(en)
|
2009-02-21 |
2017-05-30 |
Sofradim Production |
Medical devices with an activated coating
|
|
US8512728B2
(en)
|
2009-02-21 |
2013-08-20 |
Sofradim Production |
Method of forming a medical device on biological tissue
|
|
US8877170B2
(en)
|
2009-02-21 |
2014-11-04 |
Sofradim Production |
Medical device with inflammatory response-reducing coating
|
|
CA2753188A1
(en)
|
2009-02-21 |
2010-08-26 |
Tyco Healthcare Group Lp |
Medical devices having activated surfaces
|
|
GB0903207D0
(en)
|
2009-02-25 |
2009-04-08 |
Ucb Pharma Sa |
Method for expressing multimeric proteins
|
|
WO2010097435A1
(en)
|
2009-02-25 |
2010-09-02 |
Ucb Pharma, S.A. |
Method for producing antibodies
|
|
GB0904214D0
(en)
|
2009-03-11 |
2009-04-22 |
Ucb Pharma Sa |
Biological products
|
|
WO2011023680A2
(en)
|
2009-08-24 |
2011-03-03 |
Cytos Biotechnology Ag |
Processes for the synthesis and purification of heterobifunctional cross-linkers
|
|
GB0916881D0
(en)
*
|
2009-09-25 |
2009-11-11 |
Electrophoretics Ltd |
Mass labels
|
|
GB201005063D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
|
GB0922435D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
Method
|
|
GB0922434D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
antibodies and fragments thereof
|
|
US8734798B2
(en)
|
2009-10-27 |
2014-05-27 |
Ucb Pharma S.A. |
Function modifying NAv 1.7 antibodies
|
|
US9234037B2
(en)
|
2009-10-27 |
2016-01-12 |
Ucb Biopharma Sprl |
Method to generate antibodies to ion channels
|
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
|
CA2791930A1
(en)
|
2010-03-11 |
2011-09-15 |
Kerry Louise Tyson |
Pd-1 antibody
|
|
WO2011117745A2
(en)
|
2010-03-25 |
2011-09-29 |
Sofradim Production |
Surgical fasteners and methods for sealing wounds
|
|
EP2550031B1
(de)
|
2010-03-25 |
2015-08-19 |
Sofradim Production |
Medizinische vorrichtungen mit funktionellen klebstoffen
|
|
WO2012006147A1
(en)
|
2010-06-29 |
2012-01-12 |
Tyco Healthcare Group Lp |
Microwave-powered reactor and method for in situ forming implants
|
|
AU2011273102A1
(en)
|
2010-07-01 |
2013-01-31 |
Sofradim Production |
Medical device with predefined activated cellular integration
|
|
AU2011284449B2
(en)
|
2010-07-27 |
2015-07-23 |
Sofradim Production |
Polymeric fibers having tissue reactive members
|
|
ME02734B
(de)
|
2011-01-14 |
2017-10-20 |
Ucb Biopharma Sprl |
Antikörpermodule zur bindung an il-17a und il-17f
|
|
TWI719112B
(zh)
|
2011-03-16 |
2021-02-21 |
賽諾菲公司 |
雙重v區類抗體蛋白質之用途
|
|
WO2012133182A1
(ja)
|
2011-03-30 |
2012-10-04 |
富士フイルム株式会社 |
ポリエーテル化合物、該ポリエーテル化合物を用いた硬化剤、及び該ポリエーテル化合物の製造方法
|
|
US10752676B2
(en)
|
2011-09-16 |
2020-08-25 |
Ucb Biopharma Sprl |
Neutralising antibodies to the major exotoxins TCDA and TCDB of Clostridium difficile
|
|
SI2776466T1
(sl)
|
2011-11-11 |
2017-12-29 |
Ucb Biopharma Sprl |
Protitelesa, ki se vežejo na albumin in njihovi vezavni fragmenti
|
|
GB201208370D0
(en)
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Antibodies
|
|
WO2014001557A1
(en)
|
2012-06-28 |
2014-01-03 |
Ucb Pharma S.A. |
A method for identifying compounds of therapeutic interest
|
|
US9775928B2
(en)
|
2013-06-18 |
2017-10-03 |
Covidien Lp |
Adhesive barbed filament
|
|
GB201315487D0
(en)
|
2013-08-30 |
2013-10-16 |
Ucb Pharma Sa |
Antibodies
|
|
SI3021859T1
(en)
|
2013-10-25 |
2018-04-30 |
Psioxus Therapeutics Limited |
Oncolytic adenoviruses equipped with heterologous genes
|
|
GB201320066D0
(en)
|
2013-11-13 |
2013-12-25 |
Ucb Pharma Sa |
Biological products
|
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
GB201406608D0
(en)
|
2014-04-12 |
2014-05-28 |
Psioxus Therapeutics Ltd |
Virus
|
|
GB201409558D0
(en)
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
|
GB201411320D0
(en)
|
2014-06-25 |
2014-08-06 |
Ucb Biopharma Sprl |
Antibody construct
|
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
|
GB201412658D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
GB201412659D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
JP2018515082A
(ja)
|
2015-04-30 |
2018-06-14 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
代謝障害を処置するための抗ap2抗体及び抗原結合剤
|
|
GB201508180D0
(en)
|
2015-05-13 |
2015-06-24 |
Ucb Biopharma Sprl |
Antibodies
|
|
CN113940996A
(zh)
|
2015-05-27 |
2022-01-18 |
Ucb生物制药私人有限公司 |
用于治疗神经系统疾病的方法
|
|
GB201510758D0
(en)
|
2015-06-18 |
2015-08-05 |
Ucb Biopharma Sprl |
Novel TNFa structure for use in therapy
|
|
TN2017000543A1
(en)
|
2015-07-06 |
2019-04-12 |
Ucb Biopharma Sprl |
Tau-binding antibodies
|
|
MA41670A1
(fr)
|
2015-07-06 |
2018-05-31 |
Ucb Biopharma Sprl |
Anticorps se liant a tau
|
|
GB201601077D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibody molecule
|
|
GB201601073D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201601075D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies molecules
|
|
DK3359688T3
(da)
|
2015-10-05 |
2021-08-23 |
Biogen Ma Inc |
Molekylære signaturer til anvendelse til diagnose og analyse af respons på behandling af autoimmune sygdomme
|
|
RU2754683C2
(ru)
|
2015-10-27 |
2021-09-06 |
Юсб Биофарма Срл |
Способы лечения с использованием анти-il-17a антител
|
|
GB201521389D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Method
|
|
GB201521383D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl And Ucb Celltech |
Method
|
|
GB201521382D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521391D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521393D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201522394D0
(en)
|
2015-12-18 |
2016-02-03 |
Ucb Biopharma Sprl |
Antibodies
|
|
JP7328761B2
(ja)
|
2016-01-11 |
2023-08-17 |
インヒブルクス インコーポレイテッド |
多価多重特異性ox40結合融合タンパク質
|
|
JP7133544B2
(ja)
|
2016-05-01 |
2022-09-08 |
ユーシービー バイオファルマ エスアールエル |
親和性を操作した血清タンパク質担体結合ドメイン
|
|
GB201610198D0
(en)
|
2016-06-10 |
2016-07-27 |
Ucb Biopharma Sprl |
Anti-ige antibodies
|
|
TWI640536B
(zh)
|
2016-06-20 |
2018-11-11 |
克馬伯有限公司 |
抗體
|
|
SG10201913858WA
(en)
|
2016-08-26 |
2020-03-30 |
Agency Science Tech & Res |
Macrophage stimulating protein receptor (or ron - recepteur d' origine nantais) antibodies and uses thereof
|
|
IL303187A
(en)
|
2016-08-29 |
2023-07-01 |
Akamis Bio Ltd |
Adenovirus with bispecific T cell activator
|
|
GB201616596D0
(en)
|
2016-09-29 |
2016-11-16 |
Nascient Limited |
Epitope and antibodies
|
|
WO2018083257A1
(en)
|
2016-11-03 |
2018-05-11 |
Psioxus Therapeutics Limited |
Oncolytic adenovirus encoding transgenes
|
|
WO2018083258A1
(en)
|
2016-11-03 |
2018-05-11 |
Psioxus Therapeutics Limited |
Oncolytic adenovirus encoding at least three transgenes
|
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
|
GB201621635D0
(en)
|
2016-12-19 |
2017-02-01 |
Ucb Biopharma Sprl |
Crystal structure
|
|
GB201621728D0
(en)
|
2016-12-20 |
2017-02-01 |
Ucb Biopharma Sprl |
Methods
|
|
EP3824906A1
(de)
|
2016-12-21 |
2021-05-26 |
Amgen Inc. |
Anti-tnf alpha antikörperformulierungen
|
|
WO2018183366A1
(en)
|
2017-03-28 |
2018-10-04 |
Syndax Pharmaceuticals, Inc. |
Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
|
|
JP7537874B2
(ja)
|
2017-05-19 |
2024-08-21 |
シンダックス ファーマシューティカルズ, インコーポレイテッド |
併用療法
|
|
CA3063652A1
(en)
|
2017-06-01 |
2018-12-06 |
Psioxus Therapeutics Limited |
Oncolytic virus and method
|
|
PE20201462A1
(es)
|
2017-09-05 |
2020-12-17 |
Gladiator Biosciences Inc |
Metodo de direccionamiento de exosomas
|
|
GB201802486D0
(en)
|
2018-02-15 |
2018-04-04 |
Ucb Biopharma Sprl |
Methods
|
|
PT3806898T
(pt)
|
2018-06-18 |
2025-12-02 |
UCB Biopharma SRL |
Antagonista de gremlin-1 para utilização no tratamento do cancro
|
|
GB201811368D0
(en)
|
2018-07-11 |
2018-08-29 |
Ucb Biopharma Sprl |
Antibody
|
|
BR112021002164A2
(pt)
|
2018-08-13 |
2021-08-03 |
Inhibrx, Inc. |
polipeptídeos de ligação a ox40 e usos dos mesmos
|
|
KR20260014044A
(ko)
|
2018-10-16 |
2026-01-29 |
유씨비 바이오파마 에스알엘 |
중증근무력증의 치료 방법
|
|
GB201900732D0
(en)
|
2019-01-18 |
2019-03-06 |
Ucb Biopharma Sprl |
Antibodies
|
|
EP3947457A1
(de)
|
2019-03-26 |
2022-02-09 |
ASLAN Pharmaceuticals Pte Ltd |
Behandlung mit verwendung von anti-il-13r-antikörper oder bindefragment davon
|
|
GB201917480D0
(en)
|
2019-11-29 |
2020-01-15 |
Univ Oxford Innovation Ltd |
Antibodies
|
|
WO2021164722A1
(zh)
|
2020-02-21 |
2021-08-26 |
江苏恒瑞医药股份有限公司 |
抗il-2抗体、其抗原结合片段及其医药用途
|
|
CN115397860B
(zh)
|
2020-05-14 |
2025-06-13 |
江苏恒瑞医药股份有限公司 |
抗cd25抗体、其抗原结合片段及其医药用途
|
|
US20230220111A1
(en)
|
2020-07-02 |
2023-07-13 |
Beijing Tuo Jie Biopharmaceutical Co. Ltd. |
Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
|
|
BR112023001359A2
(pt)
|
2020-07-27 |
2023-02-14 |
Tuojie Biotech Shanghai Co Ltd |
Conjugado de anticorpo-fármaco anti-cd79b, método de preparação do mesmo e uso farmacêutico do mesmo
|
|
CN116348494A
(zh)
|
2020-10-13 |
2023-06-27 |
阿尔米雷尔有限公司 |
双特异性分子和使用其的治疗方法
|
|
JP2023547795A
(ja)
|
2020-10-15 |
2023-11-14 |
ユーシービー バイオファルマ エスアールエル |
Cd45を多量体化する結合分子
|
|
GB202102227D0
(en)
|
2021-02-17 |
2021-03-31 |
UCB Biopharma SRL |
Antibodies
|
|
JP2024518724A
(ja)
|
2021-04-25 |
2024-05-02 |
江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 |
抗masp2抗体、その抗原結合断片および医薬用途
|
|
BR112023026111A2
(pt)
|
2021-06-28 |
2024-03-05 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Anticorpo anti-cd40, fragmento de ligação ao antígeno e uso médico do mesmo
|
|
WO2023285878A1
(en)
|
2021-07-13 |
2023-01-19 |
Aviation-Ophthalmology |
Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
|
|
CN117642424A
(zh)
|
2021-08-25 |
2024-03-01 |
江苏恒瑞医药股份有限公司 |
一种含融合蛋白的药物组合物
|
|
CA3231320A1
(en)
|
2021-09-15 |
2023-03-23 |
Zhiliang CAO |
Protein specifically binding to pd-1 and pharmaceutical use thereof
|
|
WO2023075702A1
(en)
|
2021-10-29 |
2023-05-04 |
Aslan Pharmaceuticals Pte Ltd |
Anti-il-13r antibody formulation
|
|
WO2023140780A1
(en)
|
2022-01-24 |
2023-07-27 |
Aslan Pharmaceuticals Pte Ltd. |
Method of treating inflammatory disease
|
|
CN118510815A
(zh)
|
2022-02-11 |
2024-08-16 |
江苏恒瑞医药股份有限公司 |
免疫缀合物及其用途
|
|
TW202337905A
(zh)
|
2022-02-23 |
2023-10-01 |
新加坡商亞獅康私人有限公司 |
抗il13r抗體之糖基化形式
|
|
GB202205203D0
(en)
|
2022-04-08 |
2022-05-25 |
UCB Biopharma SRL |
Combination with inhibitor
|
|
GB202205200D0
(en)
|
2022-04-08 |
2022-05-25 |
Ucb Biopharma Sprl |
Combination with chemotherapy
|
|
EP4590335A1
(de)
|
2022-08-26 |
2025-07-30 |
ASLAN Pharmaceuticals Pte Ltd |
Hochkonzentrierte anti-il13r-antikörperformulierung
|
|
GB202214756D0
(en)
|
2022-10-07 |
2022-11-23 |
Univ Oxford Innovation Ltd |
Product
|
|
EP4626549A1
(de)
|
2022-11-28 |
2025-10-08 |
UCB Biopharma SRL |
Behandlung von fibromyalgie
|
|
EP4643877A1
(de)
|
2022-12-28 |
2025-11-05 |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Zusammensetzung eines cd40-bindenden moleküls und pharmazeutische verwendung davon
|
|
EP4681729A1
(de)
|
2023-03-15 |
2026-01-21 |
Shanghai Mabgen Biotech Ltd. |
Pharmazeutische zusammensetzung mit pd-1/pvrig/tigit-bindungsprotein und medizinische verwendung davon
|
|
GB202318820D0
(en)
|
2023-12-08 |
2024-01-24 |
UCB Biopharma SRL |
Antibodies
|
|
TW202540204A
(zh)
|
2024-01-26 |
2025-10-16 |
西班牙商阿爾米雷爾有限公司 |
雙特異性分子及使用其的治療方法
|
|
GB202403366D0
(en)
|
2024-03-08 |
2024-04-24 |
Univ Oxford Innovation Ltd |
Product
|
|
WO2025196217A1
(en)
|
2024-03-21 |
2025-09-25 |
UCB Biopharma SRL |
Treatment of tauopathies with tau-binding antibodies
|
|
WO2026027660A1
(en)
|
2024-08-02 |
2026-02-05 |
UCB Biopharma SRL |
Formulations of anti-gremlin-1 antibodies
|